Lindstrom E, Rizoska B, Henderson I, Terelius Y, Jerling M, Edenius C, et al. Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711. J Transl Med. 2018;16:125 pubmed publisher

Yi W, Su M, Shi Y, Jiang S, Xu S, Lei T. Degraded melanocores are incompetent to protect epidermal keratinocytes against UV damage. Cell Cycle. 2018;17:844-857 pubmed publisher

Schaal J, Tran D, Subramanian A, Patel R, Laragione T, Roberts K, et al. Suppression and resolution of autoimmune arthritis by rhesus ?-defensin-1, an immunomodulatory macrocyclic peptide. PLoS ONE. 2017;12:e0187868 pubmed publisher

Jiang H, Cheng X, Shi G, Hu L, Inoue A, Yamamura Y, et al. Cathepsin K-mediated Notch1 activation contributes to neovascularization in response to hypoxia. Nat Commun. 2014;5:3838 pubmed publisher

Zou F, Schäfer N, Palesch D, Brücken R, Beck A, Sienczyk M, et al. Regulation of cathepsin G reduces the activation of proinsulin-reactive T cells from type 1 diabetes patients. PLoS ONE. 2011;6:e22815 pubmed publisher

Ma D, Yao J, Kuo M, See L, Lin K, Chen S, et al. Generation of endostatin by matrix metalloproteinase and cathepsin from human limbocorneal epithelial cells cultivated on amniotic membrane. Invest Ophthalmol Vis Sci. 2007;48:644-51 pubmed

Cheng T, Hitomi K, van Vlijmen Willems I, de Jongh G, Yamamoto K, Nishi K, et al. Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site. A novel clue for the role of cystatin M/E in epidermal cornification. J Biol Chem. 2006;281:15893-9 pubmed